Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets

Area of Science:

• Nephrology
• Immunology
• Transplantation Biology

Background:

• Renal transplantation is the definitive treatment for end-stage renal disease, but long-term graft survival is limited.
• Chronic allograft nephropathy (CAN) is characterized by tubular atrophy, arterial fibrosis, interstitial fibrosis, and glomerulosclerosis, leading to kidney function decline.
• Both humoral and cell-mediated immunity, involving T cells, cytokines, CD20+ B cells, and antibodies, contribute to long-term renal transplant rejection.

Purpose of the Study:

• To review current literature on factors affecting long-term renal transplant survival.
• To identify anti-proliferative agents that can suppress the immune system and enhance graft longevity.
• To provide insights into improving long-term outcomes for kidney transplant recipients.

Main Methods:

• Literature review of current research on renal transplantation and chronic allograft nephropathy.
• Analysis of histopathological changes associated with graft failure.
• Investigation of immunological mechanisms and risk factors in long-term rejection.

Main Results:

• Key histopathological changes in CAN include tubular atrophy, arterial fibrosis, interstitial fibrosis, and glomerulosclerosis.
• Immune factors like T cells, cytokines, B cells, and antibodies are critical in long-term rejection.
• Risk factors such as HLA-mismatching, prior rejection episodes, age mismatch, and smoking negatively impact graft survival.

Conclusions:

• Understanding the mechanisms of long-term rejection is crucial for improving renal transplant survival.
• Anti-proliferative agents hold potential for suppressing immune responses and extending graft life.
• Further research into immunomodulatory strategies is needed to enhance long-term renal allograft outcomes.